Maze Therapeutics MAZE
NASDAQ MAZE
$34.74 -0.17 (-0.49%)
As of: Nov 10, 2026 · 2:24 PM EST

Maze Therapeutics (MAZE) Net Margin (2024 - 2026)

Updated

Maze Therapeutics' Net Margin was -121.04% in Q1 2026.

Analysis

Maze Therapeutics (MAZE) Net Margin (2024 - 2026) Analysis & Trends

For FY2024, Net Margin at Maze Therapeutics came in at 2.03%.

  • The Q1 2026 figure marks the highest quarterly Net Margin since Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 26.44%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 0.83%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 24.24%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 28.01%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 22.65%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 16.30%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 37.28%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 29.27%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 19.55%
10 Maze Therapeutics 2.05 Bn 561.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -121.04%
Sep 30, 2024 -990.08%
Jun 30, 2024 8.41%
API Access

Maze Therapeutics Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=MAZE&period=max&api_key=YOUR_API_KEY